Study study type
PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone
IMpower-110 (TC3 or IC3), 2020

          NCT02409342    		RCTmNSCLC - L1 - PDL1 positiveatezolizumabplatinum chemotherapyPD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC 3)107 / 98some concern
    		 conclusif
    • demonstrated 41 % decrease in deaths (OS) (PE)
    • suggested 41 % decrease in PFS (extension)
    • suggested 37 % decrease in progression or deaths (PFS)
    IMpower-110 (TC2/3 or IC2/3), 2020

              NCT02409342      		RCTmNSCLC - L1 - PDL1 positiveatezolizumabplatinium chemotherapyPD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC2/3)166 / 162some concern
      		 suggested
      • suggested 28 % decrease in deaths (OS) (PE)
      • suggested 36 % decrease in PFS (extension)
      • suggested 33 % decrease in progression or deaths (PFS)
      IMpower-110 (TC1/2/3 or IC1/2/3), 2020
        NCT02409342      		RCTmNSCLC - L1 - PDL1 positiveatezolizumabplatinium chemotherapyPD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC 1/2/3)277 / 277some concern
      		 inconclusive
      • inconclusive 17 % decrease in deaths (OS) (PE)
      • suggested 28 % decrease in PFS (extension)
      • suggested 23 % decrease in progression or deaths (PFS)

      mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

      versus docetaxel
      atezolizumab alone
      OAK (all population), 2016
        NCT02008227      		RCTmNSCLC - L2 - all populationatelozumabdocetaxelpatients with locally advanced or metastatic (IIIB and IV) non-small cell lung cancer (NSCLC) who have failed platinum therapy613 / 612some concern
      		 conclusif
      • demonstrated 20 % decrease in deaths (OS) (PE)
      POPLAR, 2016
        NCT01903993      		RCTmNSCLC - L2 - all populationatezolizumabdocetaxelpatients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy144 / 143some concern
      		 conclusif
      • demonstrated 27 % decrease in deaths (OS) (PE)

      mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

      versus docetaxel
      atezolizumab alone
      OAK (PDL1 TC 1/2/3), 2016
        NCT02008227      		RCTmNSCLC - L2 - PDL1 positiveatelozumabdocetaxelpatients with locally advanced or metastatic (IIIB and IV) non-small cell lung cancer (NSCLC) who have failed platinum therapy, only patients with PDL1 TC 1/2/3347 / 337some concern
      		 conclusif
      • demonstrated 23 % decrease in deaths (OS) (PE)
      • statistically significant 8.6-fold increase in DOR

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons